egl-9 family hypoxia-inducible factor 3 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored EGLN3P1 profile across patient tissues and cancer cell-line models. EGLN3P1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, EGLN3P1 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, EGLN3P1 RNA expression shows 11,371 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, KIRC, and UVM as cancer lineages where EGLN3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EGLN3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EGLN3P1 survival associations across molecular data types. EGLN3P1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EGLN3P1 RNA expression–survival associations across cancer types. High EGLN3P1 expression shows unfavorable associations in DLBC and THCA, but favorable associations in STAD, HNSC, ACC and LUAD. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify STAD as the clearest survival context for EGLN3P1 RNA expression.
This table summarizes EGLN3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EGLN3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EGLN3P1 shows lower tumor expression in COAD and LIHC and higher tumor expression in KIRC. The KIRC box plot shows higher EGLN3P1 RNA expression in tumor versus normal tissue (log2 FC = +0.066, t-test p < 0.001).
This table shows molecular features associated with EGLN3P1 in patient tissues and cancer cell lines. In patient samples, EGLN3P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
